PMID-39161060 – 5A1MQ Dose-Response in DIO Mice
Babula JJ, et al. Dose-dependent effects of 5-amino-1-methylquinolinium (5-amino-1MQ), a nicotinamide N-methyltransferase inhibitor, on metabolic parameters in diet-induced obese mice. Diabetes Obes Metab. 2024;26(11):5432-5443.
Quick Reference
| Property | Value |
|---|---|
| PMID | 39161060 |
| DOI | 10.1111/dom.15879 |
| Year | 2024 |
| Journal | Diabetes, Obesity and Metabolism |
| Study Type | Animal in vivo |
| Evidence Level | V |
| Sample | Diet-induced obese (DIO) mice, multiple dose groups, 28-day treatment |
| Peptide(s) Studied | 5-Amino-1MQ |
Key Findings
- 28-day treatment with 5-Amino-1MQ dose-dependently limited weight gain and fat accumulation in DIO mice
- Improved glucose tolerance and insulin sensitivity at higher doses, suggesting benefit for metabolic syndrome
- Reduced hepatic fatty infiltration (liver steatosis), indicating potential for NAFLD/MAFLD management
- Pharmacokinetic analysis confirmed good systemic exposure after administration, supporting clinical dosing feasibility
- Effects were proportional to dose, establishing a clear dose-response relationship for future clinical trial design
- No significant adverse effects observed across dose groups during the 28-day period
Study Design
DIO mice were randomized to receive multiple dose levels of 5-Amino-1MQ or vehicle control for 28 days. Primary endpoints included body weight change, fat mass (by body composition analysis), glucose tolerance tests, insulin sensitivity assessments, and liver histology. Pharmacokinetic sampling was performed to characterize systemic exposure at each dose level.
Limitations
- Mouse model only — no human data generated
- 28-day duration may not capture long-term efficacy or safety signals
- DIO model, while more clinically relevant than genetic models, still has limited translatability
- No assessment of metabolite-level changes (NAD+, SAM, 1-MNA) to confirm mechanism
- Single route of administration tested
Clinical Relevance
This study is critical for clinical translation as it establishes the dose-response relationship needed for human trial design. The improvements in glucose tolerance and insulin sensitivity extend the therapeutic potential of 5-Amino-1MQ beyond simple weight loss into metabolic syndrome and pre-diabetes management. The reduction in liver fat is particularly relevant given the growing prevalence of NAFLD/MAFLD. The favorable PK profile and clean safety data over 28 days support advancement toward human studies.
Related
#research #animal-in-vivo #5-Amino-1MQ #evidence-level-V